Roscovitine attenuates renal interstitial fibrosis in diabetic mice through the TGF-β1/p38 MAPK pathway

Area of Science:

• Nephrology
• Pharmacology
• Cell Biology

Background:

• Diabetic nephropathy is a leading cause of end-stage renal disease, characterized by tubulointerstitial fibrosis.
• Roscovitine, a cyclin-dependent kinase (CDK) inhibitor, has demonstrated anti-fibrotic properties.

Purpose of the Study:

• To investigate the protective effects of roscovitine against renal fibrosis in diabetic nephropathy.
• To elucidate the underlying molecular mechanisms of roscovitine's action.

Main Methods:

• In vivo studies using diabetic mice to assess renal function and histology.
• In vitro studies using HK2 cells cultured in high glucose to evaluate tubular cell epithelial-mesenchymal transition (EMT).
• Molecular analysis of fibrotic markers, EMT markers, and signaling pathways (TGF-β1/p38MAPK).

Main Results:

• Roscovitine treatment significantly improved renal function and reduced histological damage in diabetic mice.
• Roscovitine inhibited the expression of collagen, α-SMA, and TGF-β1, while preserving E-cadherin expression.
• At the cellular level, roscovitine reduced α-SMA and ameliorated decreased E-cadherin expression in high glucose-treated HK2 cells, indicating inhibition of tubular cell EMT.
• Roscovitine exerted its anti-fibrotic effects by inhibiting the upregulation of the TGF-β1/p38MAPK pathway.

Conclusions:

• Roscovitine demonstrates significant renoprotective effects in diabetic nephropathy.
• The anti-fibrotic mechanism involves the inhibition of the TGF-β1/p38MAPK pathway, thereby preventing tubular cell EMT and subsequent fibrosis.
• Roscovitine represents a promising therapeutic agent for managing diabetic kidney disease.